Professor Ola Landgren News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Professor ola landgren. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Professor Ola Landgren Today - Breaking & Trending Today

FDA approves Oncopeptides' PEPAXTO ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

FDA approves Oncopeptides PEPAXTO ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
STOCKHOLM, Feb. 26, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO
), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration, FDA, has approved PEPAXTO
(melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. ....

United States , United Kingdom , Martyj Duvall , Anders Martin , Ola Landgren , Rolf Gulliksen , Klaas Bakker , Linda Holmstr , Jakob Lindberg , Leader Of Experimental Therapeutics Program , Myeloma Program , Sylvester Comprehensive Cancer Center , Drug Administration , Global Head Of Corporate Communications , University Of Miami Health System In , Division Of Hematology , Nasdaq Stockholm , Chief Executive Officer , New Drug Application , Chief Scientific Officer , Professor Ola Landgren , Experimental Therapeutics Program , Miami Health System , Overall Response Rate , Median Duration , Extra Medullary Disease ,

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Martyj Duvall , Anders Martin , Ola Landgren , Rolf Gulliksen , Klaas Bakker , Linda Holmstr , Jakob Lindberg , Leader Of Experimental Therapeutics Program , Myeloma Program , Sylvester Comprehensive Cancer Center , Drug Administration , Global Head Of Corporate Communications , Miami Health System In , Division Of Hematology , Nasdaq Stockholm , Chief Executive Officer , New Drug Application , Chief Scientific Officer , Professor Ola Landgren , Experimental Therapeutics Program , Miami Health System , Overall Response Rate , Median Duration , Extra Medullary Disease ,